{"doi":"10.1200/jco-25-00925","title":"Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma","abstract":"<jats:p>\n                    In the POLARIX study (ClinicalTrials.gov identifier:\n                    <jats:ext-link xmlns:xlink=\"http://www.w3.org/1999/xlink\" ext-link-type=\"uri\" xlink:href=\"https://www.clinicaltrials.gov/ct2/show/NCT03274492\">NCT03274492</jats:ext-link>\n                    ), polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) showed a significant progression-free survival (PFS) benefit versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with previously untreated intermediate- or high-risk diffuse large B-cell lymphoma (DLBCL; median follow-up: 28 months). In this 5-year update, sustained PFS benefits favoring Pola-R-CHP were observed. In the global intention-to-treat population (N = 879; median follow-up: 64.1 months), Pola-R-CHP demonstrated a significant PFS benefit over R-CHOP (hazard ratio [HR], 0.77 [95% CI, 0.62 to 0.97]), with 5-year PFS rates of 64.9% (95% CI, 59.8 to 70.0) and 59.1% (95% CI, 53.9 to 64.3), respectively. Although not statistically significant, overall survival analysis showed a HR of 0.85 (95% CI, 0.63 to 1.15) at the 5-year data cut compared with 0.94 (95% CI, 0.67 to 1.33) at the 2-year data cut. In the expanded population, 46 and 62 patients had lymphoma-related deaths in the Pola-R-CHP and R-CHOP arms, respectively. Exploratory analyses showed favorable 5-year survival rates with Pola-R-CHP in high-risk subgroups, including activated B-cell DLBCL and International Prognostic Index score 3-5. Long-term tolerability was similar between treatment arms. Findings confirm Pola-R-CHP represents a standard of care for frontline treatment of DLBCL.\n                  </jats:p>","journal":"Journal of Clinical Oncology","year":2025,"id":612908,"datarank":0.519860385419959,"base_score":3.4657359027997265,"endowment":3.4657359027997265,"self_citation_contribution":0.519860385419959,"citation_network_contribution":0.0,"self_endowment_contribution":0.519860385419959,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":31,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":404955,"name":"Gilles Salles","orcid":"0000-0002-9541-8666","position":1,"is_corresponding":false},{"id":296279,"name":"Laurie H. Sehn","orcid":"0000-0003-1860-9765","position":2,"is_corresponding":false},{"id":282395,"name":"Alex F. Herrera","orcid":"0000-0002-9665-7415","position":3,"is_corresponding":false},{"id":11108,"name":"Jonathan W. Friedberg","orcid":"0000-0002-1420-5563","position":4,"is_corresponding":false},{"id":724485,"name":"Marek Trněný","orcid":"0000-0002-6952-6073","position":5,"is_corresponding":false},{"id":1121485,"name":"Georg Lenz","orcid":"0000-0002-4728-1693","position":6,"is_corresponding":false},{"id":249997,"name":"Jeff P. Sharman","orcid":"0000-0001-5611-6115","position":7,"is_corresponding":false},{"id":774718,"name":"Charles Herbaux","orcid":"0000-0003-4910-476X","position":8,"is_corresponding":false},{"id":179807,"name":"John M. Burke","orcid":null,"position":9,"is_corresponding":false},{"id":246210,"name":"Matthew J. Matasar","orcid":"0000-0002-4581-3721","position":10,"is_corresponding":false},{"id":642187,"name":"Graham P. Collins","orcid":"0000-0002-8803-4234","position":11,"is_corresponding":false},{"id":1578450,"name":"Neha Mehta-Shah","orcid":null,"position":12,"is_corresponding":false},{"id":1578451,"name":"Lucie Oberic","orcid":"0000-0002-0039-1983","position":13,"is_corresponding":false},{"id":1578452,"name":"Adrien Chauchet","orcid":null,"position":14,"is_corresponding":false},{"id":1196206,"name":"Wojciech Jurczak","orcid":"0000-0003-1879-8084","position":15,"is_corresponding":false},{"id":713191,"name":"Yuqin Song","orcid":"0000-0001-5451-6481","position":16,"is_corresponding":false},{"id":355533,"name":"Antonio Pinto","orcid":"0000-0002-0665-9872","position":17,"is_corresponding":false},{"id":1019642,"name":"Shinya Rai","orcid":"0000-0003-3929-9751","position":18,"is_corresponding":false},{"id":1121487,"name":"Koji Izutsu","orcid":"0000-0001-9129-8057","position":19,"is_corresponding":false},{"id":226648,"name":"Richard Greil","orcid":"0000-0002-4462-3694","position":20,"is_corresponding":false},{"id":1578456,"name":"Larysa Mykhalska","orcid":null,"position":21,"is_corresponding":false},{"id":1578457,"name":"Juan M. Bergua-Burgués","orcid":"0000-0001-8229-1208","position":22,"is_corresponding":false},{"id":784863,"name":"Matthew C. Cheung","orcid":"0000-0003-3193-5872","position":23,"is_corresponding":false},{"id":1578460,"name":"Ho-Jin Shin","orcid":null,"position":24,"is_corresponding":false},{"id":270228,"name":"Greg Hapgood","orcid":"0000-0002-7980-8496","position":25,"is_corresponding":false},{"id":1578463,"name":"Eduardo Munhoz","orcid":null,"position":26,"is_corresponding":false},{"id":1382666,"name":"Pau Abrisqueta","orcid":"0000-0001-9625-7422","position":27,"is_corresponding":false},{"id":1578464,"name":"Jyh-Pyng Gau","orcid":null,"position":28,"is_corresponding":false},{"id":242784,"name":"Yanwen Jiang","orcid":"0000-0002-9894-6560","position":29,"is_corresponding":false},{"id":1578466,"name":"Bruce McCall","orcid":null,"position":30,"is_corresponding":false},{"id":1578468,"name":"Saibah Chohan","orcid":null,"position":31,"is_corresponding":false},{"id":1578469,"name":"Matthew Sugidono","orcid":"0000-0003-4883-8921","position":32,"is_corresponding":false},{"id":1578470,"name":"Mark Yan","orcid":null,"position":33,"is_corresponding":false},{"id":237602,"name":"Connie Lee Batlevi","orcid":"0000-0002-9036-9463","position":34,"is_corresponding":false},{"id":608037,"name":"Hervé Tilly","orcid":"0000-0001-7022-5246","position":35,"is_corresponding":false},{"id":107379,"name":"Christopher R. Flowers","orcid":"0000-0002-9524-3990","position":36,"is_corresponding":false},{"id":838697,"name":"Franck Morschhauser","orcid":"0000-0002-3714-9824","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma","abstract":"<jats:p>\n                    In the POLARIX study (ClinicalTrials.gov identifier:\n                    <jats:ext-link xmlns:xlink=\"http://www.w3.org/1999/xlink\" ext-link-type=\"uri\" xlink:href=\"https://www.clinicaltrials.gov/ct2/show/NCT03274492\">NCT03274492</jats:ext-link>\n                    ), polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) showed a significant progression-free survival (PFS) benefit versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with previously untreated intermediate- or high-risk diffuse large B-cell lymphoma (DLBCL; median follow-up: 28 months). In this 5-year update, sustained PFS benefits favoring Pola-R-CHP were observed. In the global intention-to-treat population (N = 879; median follow-up: 64.1 months), Pola-R-CHP demonstrated a significant PFS benefit over R-CHOP (hazard ratio [HR], 0.77 [95% CI, 0.62 to 0.97]), with 5-year PFS rates of 64.9% (95% CI, 59.8 to 70.0) and 59.1% (95% CI, 53.9 to 64.3), respectively. Although not statistically significant, overall survival analysis showed a HR of 0.85 (95% CI, 0.63 to 1.15) at the 5-year data cut compared with 0.94 (95% CI, 0.67 to 1.33) at the 2-year data cut. In the expanded population, 46 and 62 patients had lymphoma-related deaths in the Pola-R-CHP and R-CHOP arms, respectively. Exploratory analyses showed favorable 5-year survival rates with Pola-R-CHP in high-risk subgroups, including activated B-cell DLBCL and International Prognostic Index score 3-5. Long-term tolerability was similar between treatment arms. Findings confirm Pola-R-CHP represents a standard of care for frontline treatment of DLBCL.\n                  </jats:p>","is_dataset_classified":null,"base_score":3.4657359027997265,"endowment":3.4657359027997265,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"40991874","pmcid":"PMC12680271","openalex_id":"https://openalex.org/W4414533110","authors":[],"funders":[{"funder_name":"NCI NIH HHS","grant_id":"P30 CA008748","title":null}],"total_grants":1,"fwci":23.5132,"citation_percentile":0.99721785,"influential_citations":0,"citation_trend":[{"year":2025,"count":4},{"year":2026,"count":27}],"oa_status":"hybrid","license":"cc-by-nc-nd","oa_locations":[{"url":"https://ascopubs.org/doi/pdfdirect/10.1200/JCO-25-00925","host_type":"journal"},{"url":"https://ascopubs.org/doi/pdfdirect/10.1200/JCO-25-00925","host_type":"publisher"},{"url":"https://doi.org/10.1200/jco-25-00925","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/40991874","host_type":"repository"},{"url":"https://lilloa.hal.science/hal-05336330","host_type":"repository"},{"url":"https://lilloa.univ-lille.fr/handle/20.500.12210/131402","host_type":"repository"},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12680271/","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC12680271","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC12680271?pdf=render","host_type":"Europe_PMC"}],"fields_of_study":["Chronic Lymphocytic Leukemia Research","Lymphoma Diagnosis and Treatment","CNS Lymphoma Diagnosis and Treatment","Humans","Lymphoma, Large B-Cell, Diffuse","Antineoplastic Combined Chemotherapy Protocols","Cyclophosphamide","Doxorubicin","Vincristine","Prednisone","Rituximab","Middle Aged","Male","Female","Aged","Adult","Progression-Free Survival","Antibodies, Monoclonal, Humanized","Aged, 80 and over","Young Adult","Antibodies, Monoclonal","Immunoconjugates"],"mesh_terms":["Rituximab","Progression-Free Survival","Adult","Aged","Aged, 80 and over","Antibodies, Monoclonal","Antineoplastic Combined Chemotherapy Protocols","Cyclophosphamide","Doxorubicin","Female","Humans","Male","Middle Aged","Prednisone","Vincristine","Lymphoma, Large B-Cell, Diffuse","Immunoconjugates","Young Adult","Antibodies, Monoclonal, Humanized"],"keywords":["Prednisone","International Prognostic Index","Tolerability","Lymphoma","Overall survival","Population","Diffuse large B-cell lymphoma","Progression-free survival","Cohort"],"sdg_mappings":[],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[{"name":"nct"}],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-02T05:33:24.666366Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}